KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Short-Term Debt issuances (2017 - 2025)

Boston Scientific's Short-Term Debt issuances history spans 8 years, with the latest figure at -$192.0 million for Q1 2025.

  • For Q1 2025, Short-Term Debt issuances changed N/A year-over-year to -$192.0 million; the TTM value through Dec 2025 reached -$5.0 million, down 102.67%, while the annual FY2025 figure was -$196.0 million, 204.81% down from the prior year.
  • Short-Term Debt issuances for Q1 2025 was -$192.0 million at Boston Scientific, down from $187.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $223.0 million in Q1 2022 and bottomed at -$192.0 million in Q1 2025.
  • The 4-year median for Short-Term Debt issuances is -$20.5 million (2023), against an average of -$1.2 million.
  • The largest annual shift saw Short-Term Debt issuances skyrocketed 76.13% in 2023 before it surged 4775.0% in 2024.
  • A 4-year view of Short-Term Debt issuances shows it stood at -$155.0 million in 2022, then soared by 97.42% to -$4.0 million in 2023, then soared by 4775.0% to $187.0 million in 2024, then plummeted by 202.67% to -$192.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Short-Term Debt issuances are -$192.0 million (Q1 2025), $187.0 million (Q4 2024), and -$4.0 million (Q4 2023).